News

In Phase III studies, degarelix produced a significant reduction in levels of testosterone within three days in more than 96% of study patients. Testosterone plays a major role

Myozyme is the only approved treatment for Pompe disease, a progressively debilitating disease that manifests as a broad spectrum of clinical symptoms. The positive Committee for Medicinal Products

The FDA has indicated that it intends to advise Nuvo of its decision regarding Pennsaid approvability by August 5, 2009 under the Prescription Drug User Fee Act. Pennsaid,

The nominal 20-year patent term extends to October 13, 2024. ITMN-191 is an inhibitor of the hepatitis C virus (HCV) NS3/4A protease. ITMN-191 is being developed with InterMune’s

Sales for the quarter were $10.0 million, 11% greater than the prior year, while sales for the year were $37.6 million, 10% greater than in 2007. The company

ProLindac is Access’s novel DACH platinum prodrug currently in Phase II clinical studies which has been shown to be active in a wide variety of solid tumors in

According to the company, statistically significant reductions were observed in the overall target plaque severity score (OTPSS), as well as in the individual signs of psoriasis, such as

This is the third cancer indication being explored by Aveo for the potential combined use of AV-951 with leading targeted agents or chemotherapeutic regimens. The company has launched

The trial will enroll 16 ambulatory boys with Duchenne muscular dystrophy (DMD) and initially evaluate multiple intravenous doses of AVI-4658 between 0.5-4mg/kg. This is an open label, 12